topotecan has been researched along with Cystadenocarcinoma, Papillary in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beshara, N; Faught, W; Fung Kee Fung, M | 1 |
| Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
| Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
| Bădulescu, A; Bădulescu, F; Popescu, CF; Schenker, M; Stoica, Z | 1 |
| Aguilar-Cordova, E; Hasenburg, A; Kaplan, A; Kaufman, RH; Kieback, CC; Kieback, DG; Nyberg-Hoffman, C; Ramzy, I; Rojas-Martinez, A; Tong, XW | 1 |
| Shen, K; Sun, Z; Xu, X | 1 |
3 trial(s) available for topotecan and Cystadenocarcinoma, Papillary
| Article | Year |
|---|---|
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Thymidine kinase gene therapy with concomitant topotecan chemotherapy for recurrent ovarian cancer.
Topics: Acyclovir; Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenoviridae; Adult; Aged; Antiviral Agents; Combined Modality Therapy; Cystadenocarcinoma, Papillary; DNA; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polymerase Chain Reaction; Thymidine Kinase; Topotecan | 2000 |
3 other study(ies) available for topotecan and Cystadenocarcinoma, Papillary
| Article | Year |
|---|---|
The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Endometrioid; Cystadenocarcinoma, Papillary; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Topotecan | 2002 |
The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
Topics: CA-125 Antigen; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Topotecan; Treatment Outcome | 2005 |
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |